Brief: Annovis Bio Announces Last Patient Last Visit In The Phase Iii Study Of Buntanetap In Parkinson’S Disease
05/12/2023 12:30
Dec 5 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE
III
STUDY OF BUNTANETAP IN PARKINSON’S DISEASE
* ANNOVIS BIO INC - TOPLINE DATA RESULTS ARE EXPECTED IN
JANUARY
2024
Source text for Eikon: ID:nGNX8p7WkV
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman